The Magnitude of MTB and Rifampicin Resistance MTB Using Xpert-MTB/RIF Assay Among Tuberculosis Suspected Patients in Gedeo Zone, Southern Ethiopia

References

• KhanM, RajaZ, AhmedH, RaufA. A pattern of tuberculosis infection an overview. Pakistan J Biotechnol. 2019;16(3):153–161.
   Google Scholar
• World Health Organization. Global status report on alcohol and health 2018. World Health Organization; 2019.
   Google Scholar
• World Health Organization. Tracking universal health coverage: first global monitoring report. World Health Organization; 2015.
   Google Scholar
• World Health Organization. Global tuberculosis report 2020: executive summary; 2020.
   Google Scholar
• World Health Organization. Global tuberculosis report 2013. World Health Organization; 2013.
   Google Scholar
• MiglioriGB, TiberiS, García-BasteiroAL, DuarteR. Tuberculosis and its future in the COVID-19 era: the pulmonology series 2021. Pulmonology. 2021;27:94–96.33272908
   PubMed Web of Science ®Google Scholar
• UplekarM, WeilD, LonnrothK, et al. WHO’s new end TB strategy. Lancet. 2015;385(9979):1799–1801. doi:10.1016/S0140-6736(15)60570-025814376
   PubMed Web of Science ®Google Scholar
• MiglioriGB, DhedaK, CentisR, et al. Review of multidrug‐resistant and extensively drug‐resistant TB: global perspectives with a focus on Sub‐Saharan Africa. Trop Med Int Health. 2010;15(9):1052–1066. doi:10.1111/j.1365-3156.2010.02581.x20545927
   PubMed Web of Science ®Google Scholar
• ZignolM, GemertW, FalzonD, et al. Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007–2010. Bull World Health Organ. 2012;90:111–119. doi:10.2471/BLT.11.09258522423162
   PubMed Web of Science ®Google Scholar
• World Health Organization. Rapid implementation of the Xpert MTB/RIF diagnostic test: technical and operational’How-to’; practical considerations. World Health Organization; 2011:9241501561.
   Google Scholar
• MulisaG, WorknehT, HordofaN, SuaudiM, AbebeG, JarsoG. Multidrug-resistant Mycobacterium tuberculosis and associated risk factors in Oromia Region of Ethiopia. Int J Infect Dis. 2015;39:57–61. doi:10.1016/j.ijid.2015.08.01326327121
   PubMed Web of Science ®Google Scholar
• GirumT, MuktarE, LentiroK, WondiyeH, ShewangizawM. Epidemiology of multidrug-resistant tuberculosis (MDR-TB) in Ethiopia: a systematic review and meta-analysis of the prevalence, determinants and treatment outcome. Trop Dis Travel Med Vaccines. 2018;4(1):1–12. doi:10.1186/s40794-018-0065-529507748
   PubMedGoogle Scholar
• EshetieS, GizachewM, DagnewM, et al. Multidrug resistant tuberculosis in Ethiopian settings and its association with previous history of anti-tuberculosis treatment: a systematic review and meta-analysis. BMC Infect Dis. 2017;17(1):1–12. doi:10.1186/s12879-017-2323-y28049444
   PubMed Web of Science ®Google Scholar
• BālaśelṭānEYS, MacroO. Ethiopia demographic and health survey, 2005. Central Statistical Authority; 2006.
   Google Scholar
• WasihunAG, HailuGG, DejeneTA. Prevalence of Mycobacterium tuberculosis (Rifampicin-Resistant MTB) and associated risk actors among pulmonary presumptive TB patients in Eastern Amhara, Ethiopia: 2015–2019. Infect Dis Ther. 2021;10:1299–1308.33950463
   PubMed Web of Science ®Google Scholar
• DestaK, AsratD, LemmaE, GebeyehuM, FelekeB. Drug susceptibility of Mycobacterium tuberculosis isolates from smear negative pulmonary tuberculosis patients, Addis Ababa, Ethiopia. Ethiop J Health Dev. 2008;22(2):212–215.
   Google Scholar
• NicolMP, WorkmanL, IsaacsW, et al. Accuracy of the Xpert MTB/RIF test for the diagnosis of pulmonary tuberculosis in children admitted to hospital in Cape Town, South Africa: a descriptive study. Lancet Infect Dis. 2011;11(11):819–824. doi:10.1016/S1473-3099(11)70167-021764384
   PubMed Web of Science ®Google Scholar
• KimCH, HyunIG, HwangYI, et al. Identification of Mycobacterium tuberculosis and rifampin resistance in clinical specimens using the Xpert MTB/RIF assay. Ann Clin Lab Sci. 2015;45(1):32–38.25696008
   PubMed Web of Science ®Google Scholar
• MuluW, AberaB, YimerM, HailuT, AyeleH, AbateD. Rifampicin-resistance pattern of Mycobacterium tuberculosis and associated factors among presumptive tuberculosis patients referred to Debre Markos Referral Hospital, Ethiopia: a cross-sectional study. BMC Res Notes. 2017;10(1):1–8.28057050
   PubMedGoogle Scholar
• HordofaMW, AdelaTB. Prevalence of Refampcin mono resistant Mycobacterium tuberculosis among suspected cases attending at Yirgalem hospital. Clin Med Res. 2015;4(3):75–78. doi:10.11648/j.cmr.20150403.13
   Google Scholar
• GeletaDA, MegerssaYC, GudetaAN, AkaluGT, DebeleMT, TuluKD. Xpert MTB/RIF assay for diagnosis of pulmonary tuberculosis in sputum specimens in remote health care facility. BMC Microbiol. 2015;15(1):1–6. doi:10.1186/s12866-015-0566-625591663
   PubMed Web of Science ®Google Scholar
• MehariK, AsmelashT, HailekirosH, et al. Prevalence and factors associated with multidrug-resistant tuberculosis (MDR-TB) among presumptive MDR-TB patients in Tigray Region, Northern Ethiopia. Can J Infect Dis Med Microbiol. 2019;2019:1–8. doi:10.1155/2019/2923549
   Web of Science ®Google Scholar
• AdaneK, AmeniG, BekeleS, AbebeM, AseffaA. Prevalence and drug resistance profile of Mycobacterium tuberculosis isolated from pulmonary tuberculosis patients attending two public hospitals in East Gojjam zone, northwest Ethiopia. BMC Public Health. 2015;15(1):1–8. doi:10.1186/s12889-015-1933-925563658
   PubMed Web of Science ®Google Scholar
• NigusD, LingerewW, BeyeneB, TamiruA, LemmaM, MelakuM. Prevalence of multi drug resistant tuberculosis among presumptive multi drug resistant tuberculosis cases in Amhara National Regional State, Ethiopia. J Mycobac Dis. 2014;4(152):2161–1068. doi:10.4172/2161-1068.1000152
   Google Scholar
• TahiriL, AzzouziH, SqualliG, AbourazzakF, HarzyT. Celiac disease causing severe osteomalacia: an association still present in Morocco!Pan Afr Med J. 2014;19. doi:10.11604/pamj.2014.19.43.2757
   Google Scholar
• FarraA, ManirakizaA, YambiyoBM, et al. editors. Surveillance of rifampicin resistance with GeneXpert MTB/RIF in the National Reference Laboratory for tuberculosis at the Institut Pasteur in Bangui, 2015–2017. In: Open Forum Infectious Diseases. US: Oxford University Press; 2019.
   Google Scholar
• DagnraA, MlagaK, AdjohK, KadangaE, DisseK, AdekambiT. Prevalence of multidrug-resistant tuberculosis cases among HIV-positive and HIV-negative patients eligible for retreatment regimen in Togo using GeneXpert MTB/RIF. New Microbes New Infect. 2015;8:24–27. doi:10.1016/j.nmni.2015.09.00128626586
   PubMedGoogle Scholar
• YinL, QinG, QianH-Z, et al. Continued spread of HIV among injecting drug users in southern Sichuan Province, China. Harm Reduct J. 2007;4(1):1–7. doi:10.1186/1477-7517-4-617201933
   PubMedGoogle Scholar
• SinshawW, KebedeA, BitewA, et al. Prevalence of tuberculosis, multidrug resistant tuberculosis and associated risk factors among smear negative presumptive pulmonary tuberculosis patients in Addis Ababa, Ethiopia. BMC Infect Dis. 2019;19(1):1–15. doi:10.1186/s12879-019-4241-730606108
   PubMed Web of Science ®Google Scholar
• HamusseSD, TeshomeD, HussenMS, DemissieM, LindtjørnB. Primary and secondary anti-tuberculosis drug resistance in Hitossa District of Arsi zone, Oromia regional state, Central Ethiopia. BMC Public Health. 2016;16(1):1–10. doi:10.1186/s12889-016-3210-y26728978
   PubMed Web of Science ®Google Scholar
• BiruD, WoldesemayatEM. Determinants of drug-resistant tuberculosis in southern Ethiopia: a case–control study. Infect Drug Resist. 2020;13:1823. doi:10.2147/IDR.S25653632606831
   PubMed Web of Science ®Google Scholar
• ChristopherPM, WidysantoA. GeneXpert Mycobacterium tuberculosis/Rifampicin assay for molecular epidemiology of Rifampicin-Resistant Mycobacterium tuberculosis in an urban setting of Banten Province, Indonesia. Int J Mycobacteriol. 2019;8(4):351. doi:10.4103/ijmy.ijmy_138_1931793505
   PubMed Web of Science ®Google Scholar
• OdindoBO. Determinants of multi-drug resistant tuberculosis in patients in Homa Bay County Referral Hospital. Kenya: Maseno University; 2021.
   Google Scholar
• AbebeG, AbdissaK, AbdissaA, et al. Relatively low primary drug resistant tuberculosis in southwestern Ethiopia. BMC Res Notes. 2012;5(1):1–6. doi:10.1186/1756-0500-5-22522214347
   PubMedGoogle Scholar
• Sa’edHZ, Al-JabiSW. Mapping the situation of research on coronavirus disease-19 (COVID-19): a preliminary bibliometric analysis during the early stage of the outbreak. BMC Infect Dis. 2020;20(1):1–8.
   Web of Science ®Google Scholar
• HordofaGM. Multi-drug resistant Mycobacterium tuberculosis and. BMC Res Notes. 2012;5(462):266.22672795
   PubMedGoogle Scholar
• OdumEP, UdiEO. Evaluation of cardiovascular risk factors in patients with chronic kidney disease. Port Harcourt Med J. 2017;11(2):60. doi:10.4103/phmj.phmj_15_17
   Google Scholar
• SnowK, YadavR, DenholmJ, SawyerS, GrahamS. Tuberculosis among children, adolescents and young adults in the Philippines: a surveillance report. Western Pac Surveill Response J. 2018;9(4):16. doi:10.5365/wpsar.2017.8.4.011
   Google Scholar
• RahmanA, SahrinM, AfrinS, et al. Comparison of Xpert MTB/RIF assay and GenoType MTBDR plus DNA probes for detection of mutations associated with rifampicin resistance in Mycobacterium tuberculosis. PLoS One. 2016;11(4):e0152694. doi:10.1371/journal.pone.015269427054344
   PubMed Web of Science ®Google Scholar
• ArayaS, NegessoAE, TamirZ. Rifampicin-resistant Mycobacterium tuberculosis among patients with presumptive tuberculosis in Addis Ababa, Ethiopia. Infect Drug Resist. 2020;13:3451. doi:10.2147/IDR.S26302333116664
   PubMed Web of Science ®Google Scholar
• LehoursP, SiffréE, MégraudF. DPO multiplex PCR as an alternative to culture and susceptibility testing to detect Helicobacter pylori and its resistance to clarithromycin. BMC Gastroenterol. 2011;11(1):1–5. doi:10.1186/1471-230X-11-11221211058
   PubMed Web of Science ®Google Scholar
• SekaddeMP, WobudeyaE, JolobaML, et al. Evaluation of the Xpert MTB/RIF test for the diagnosis of childhood pulmonary tuberculosis in Uganda: a cross-sectional diagnostic study. BMC Infect Dis. 2013;13(1):1–8. doi:10.1186/1471-2334-13-13323280237
   PubMed Web of Science ®Google Scholar
• ChrismanCJ, AlbuquerqueP, GuimaraesAJ, NievesE, CasadevallA. Phospholipids trigger Cryptococcus neoformans capsular enlargement during interactions with amoebae and macrophages. PLoS Pathog. 2011;7(5):e1002047. doi:10.1371/journal.ppat.100204721637814
   PubMed Web of Science ®Google Scholar
• TesfayK, TesfayS, NigusE, GebreyesusA, GebreegziabiherD, AdaneK. More than half of presumptive multidrug-resistant cases referred to a tuberculosis referral laboratory in the Tigray region of Ethiopia are multidrug resistant. Int J Mycobacteriol. 2016;5(3):324–327. doi:10.1016/j.ijmyco.2016.07.00727847018
   PubMedGoogle Scholar
• IkuabePO, EbuenyiID. Prevalence of rifampicin resistance by automated Genexpert rifampicin assay in patients with pulmonary tuberculosis in Yenagoa, Nigeria. Pan Afr Med J. 2018;29. doi:10.11604/pamj.2018.29.204.14579
   Google Scholar
• TilahunM, AmeniG, DestaK, et al. Molecular epidemiology and drug sensitivity pattern of Mycobacterium tuberculosis strains isolated from pulmonary tuberculosis patients in and around Ambo Town, Central Ethiopia. PLoS One. 2018;13(2):e0193083. doi:10.1371/journal.pone.019308329447273
   PubMed Web of Science ®Google Scholar
• BarreiraD. The challenges to eliminating tuberculosis in Brazil. Epidemiologia e Serviços de Saúde. 2018;27:e00100009.29451612
   PubMed Web of Science ®Google Scholar
• KaurR, JindalN, AroraS, KatariaS. Epidemiology of rifampicin resistant tuberculosis and common mutations in rpoB gene of Mycobacterium tuberculosis: a retrospective study from six districts of Punjab (India) using Xpert MTB/RIF assay. J Lab Physicians. 2016;8(2):96. doi:10.4103/0974-2727.18078927365918
   PubMedGoogle Scholar
• MehmoodA, AbdallahK, KhandekarS, et al. Expression of extra-cellular levansucrase in Pseudomonas syringae is controlled by the in planta fitness-promoting metabolic repressor HexR. BMC Microbiol. 2015;15(1):1–11. doi:10.1186/s12866-015-0349-025591663
   PubMed Web of Science ®Google Scholar
• ReddyR, Alvarez-UriaG. Molecular epidemiology of Rifampicin resistance in Mycobacterium tuberculosis using the GeneXpert MTB/RIF assay from a rural setting in India. J Pathog. 2017;2017:1–5. doi:10.1155/2017/6738095
   Google Scholar
• ZarHJ, ConnellTG, NicolM. Diagnosis of pulmonary tuberculosis in children: new advances. Expert Rev Anti Infect Ther. 2010;8(3):277–288. doi:10.1586/eri.10.920192682
   PubMed Web of Science ®Google Scholar
• AregaB, MenbereF, GetachewY. Prevalence of rifampicin resistant Mycobacterium tuberculosis among presumptive tuberculosis patients in selected governmental hospitals in Addis Ababa, Ethiopia. BMC Infect Dis. 2019;19(1):307. doi:10.1186/s12879-019-3943-130947695
   PubMed Web of Science ®Google Scholar
• HailuAG. Prevalence of Mycobacterium tuberculosis (Rifampicin-Resistant MTB) and associated risk actors among pulmonary presumptive TB patients in Eastern Amhara, Ethiopia: 2015–2019; 2021.
   Google Scholar
• ToungoussovaOS, CaugantDA, SandvenP, MariandyshevAO, BjuneG. Drug resistance of Mycobacterium tuberculosis strains isolated from patients with pulmonary tuberculosis in Archangels, Russia. Int J Tuberc Lung Dis. 2002;6(5):406–414.12019916
   PubMed Web of Science ®Google Scholar